Result of AGM
Updated : 14:10
SEVERFIELD PLC
Results of Annual General Meeting 2020
At the Company's Annual General Meeting held at 12 noon today, 3 September, all of the resolutions were passed on a show of hands.
Copies of all the resolutions passed have been submitted to the UK Listing Authority via the National Storage Mechanism and will shortly be available for review at Financial Conduct Authority website (https://data.fca.org.uk/#/nsm/nationalstoragemechanism).
A summary of Proxies received in respect of each resolution is set out below (a "vote withheld" is not a vote in law and is not counted in the calculation of the proportion of the votes for and against the resolution):
In Favour | Against | Total | Withheld | ||||
Resolution | No of votes | % of votes | No of votes | % of votes | No of votes | No of votes | |
1. To receive and adopt the annual accounts and the reports of the Directors for the financial year ended 31 March 2020 together with the report of the auditors thereon. | 252,370,227 | 99.99 | 37,428 | 0.01 | 252,407,655 | 1,544,286 | |
2. To approve the Directors' remuneration report (other than the part containing the Directors' remuneration policy) for the financial year ended 31 March 2020 as set out in the Annual Report and Accounts 2020. | 253,671,011 | 99.90 | 242,584 | 0.10 | 253,913,595 | 38,347 | |
3. To approve the Directors' remuneration policy as set out in the Annual Report and Accounts 2020. | 239,038,916 | 94.71 | 13,347,225 | 5.29 | 252,386,141 | 1,565,800 | |
4. To declare a final dividend of 1.8p per ordinary share in respect of the year ended 31 March 2020 payable on 11th September 2020 to shareholders on the register at the close of business on 14th August 2020. | 253,953,841 | 100.00 | 4,643 | 0.00 | 253,958,484 | 3,458 | |
5. To reappoint Ian Cochrane as a Director. | 246,213,335 | 96.95 | 7,738,865 | 3.05 | 253,952,200 | 9,742 | |
6. To reappoint Alan Dunsmore as a Director. | 244,688,208 | 96.94 | 7,734,407 | 3.06 | 252,422,615 | 1,539,327 | |
7. To reappoint Derek Randall as a Director. | 246,214,661 | 96.95 | 7,733,407 | 3.05 | 253,948,068 | 13,874 | |
8. To reappoint Adam Semple as a Director. | 246,182,778 | 96.94 | 7,765,290 | 3.06 | 253,948,068 | 13,874 | |
9. To reappoint Alun Griffiths as a Director. | 253,881,404 | 99.97 | 67,338 | 0.03 | 253,948,742 | 13,200 | |
10. To reappoint Tony Osbaldiston as a Director. | 253,927,240 | 99.99 | 14,828 | 0.01 | 253,942,068 | 19,874 | |
11. To reappoint Kevin Whiteman as a Director. | 253,877,730 | 99.97 | 64,338 | 0.03 | 253,942,068 | 19,874 | |
12. To appoint Louise Hardy as a Director | 253,868,441 | 99.97 | 68,167 | 0.03 | 253,936,608 | 25,334 | |
13. To reappoint KPMG LLP as auditors of the Company to hold office until the conclusion of the next Annual General Meeting of the Company in 2021. | 253,714,453 | 99.95 | 118,823 | 0.05 | 253,833,276 | 128,666 | |
14. To authorise the Directors to determine the auditors' remuneration. | 253,920,652 | 99.99 | 17,457 | 0.01 | 253,938,109 | 23,833 | |
15. To authorise the Directors to allot securities of the Company. | 253,288,366 | 99.74 | 666,877 | 0.26 | 253,955,243 | 6,699 | |
16. To authorise the Directors to dis-apply pre-emption rights in relation to the issue of securities of the Company. | 253,628,796 | 99.88 | 300,749 | 0.12 | 253,929,545 | 32,397 | |
17. To authorise the Directors to dis-apply pre-emption rights in connection with an acquisition or specified capital investment. | 252,119,401 | 99.29 | 1,807,810 | 0.71 | 253,927,211 | 34,730 | |
18. To authorise the Company to make market purchases of the Company's ordinary shares. | 252,196,697 | 99.31 | 1,743,286 | 0.69 | 253,939,983 | 21,958 | |
19. That a general meeting of the Company (other than an annual general meeting) may be called on not less than 14 clear days' notice. | 251,970,845 | 99.23 | 1,966,700 | 0.77 | 253,937,545 | 24,397 | |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.